We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$916M
AUM Growth
+$22.5M
Cap. Flow
+$9.33M
Cap. Flow %
1.02%
Top 10 Hldgs %
50.42%
Holding
61
New
8
Increased
22
Reduced
19
Closed
5

Top Buys

Rank Stock Value
1
CALA
Calithera Biosciences, Inc
CALA
+$21.2M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$16.4M
3
CYTK icon
Cytokinetics
CYTK
+$13.3M
4
AKRO
Akero Therapeutics
AKRO
+$12.3M
5
ACIU icon
AC Immune
ACIU
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$62.5M
2
ARQL
Arqule Inc
ARQL
+$38.5M
3
BPMC
Blueprint Medicines
BPMC
+$10.5M
4
ARGX icon
argenx
ARGX
+$10.1M
5
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$8.83M

Sector Composition

Rank Sector Weight
1 Healthcare 90.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
51
Karyopharm Therapeutics
KPTI
$159M
$2.13M 0.23%
+23,684
New +$1.9M
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
$2.11M 0.23%
65,500
-135,000
-67% -$4.52M
FRTX
53
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.55M 0.17%
5,807
-1,428
-20% -$479K
MREO
54
Mereo BioPharma
MREO
$50.3M
$1.26M 0.14%
+523,382
New +$2.29M
CFRX
55
DELISTED
ContraFect Corporation
CFRX
$968K 0.11%
2,374
– –
ELDN icon
56
Eledon Pharmaceuticals
ELDN
$263M
$837K 0.09%
+46,049
New +$2.01M
ARGX icon
57
argenx
ARGX
$54.6B
– –
-80,868
Closed -$10.1M
VYGR icon
58
Voyager Therapeutics
VYGR
$189M
– –
-310,299
Closed -$5.94M
XNCR icon
59
Xencor
XNCR
$1.59B
– –
-904
Closed -$28K
VBIV
60
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
– –
-157,419
Closed -$8.83M
OMED
61
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-4,108,815
Closed -$4.27M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2019 Portfolio in Review

As of Q2 2019, BVF Inc held 61 positions worth $916M, up 2.5% from $893M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

BVF Inc's Q2 2019 filing shows 8 new, 22 increased, 19 reduced and 5 closed positions. Its largest new stake was IDEAYA Biosciences: 1,505,429 shares worth $15M. The largest sale was Array Biopharma Inc, an estimated $62.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

  • BVF Inc's largest Q2 2019 buy was IDEAYA Biosciences: 1,505,429 shares worth $15M.
  • BVF Inc added most to Calithera Biosciences, Inc in Q2 2019, an estimated $21.2M increase.
  • BVF Inc's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.5M.
  • BVF Inc fully exited argenx in Q2 2019, selling an estimated $10.1M.
  • BVF Inc's ten largest holdings make up 50% of its $916M portfolio in Q2 2019.
  • BVF Inc opened 8 new positions and closed 5 in Q2 2019.
  • BVF Inc's portfolio value rose 2.5% quarter-over-quarter to $916M.

Based on BVF Inc's 13F filing for Q2 2019, filed 14 Aug 2019.